CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Insys Pharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Insys Pharma Inc
3100 West Ray Road
Suite 201
Phone: (602) 910-2617p:602 910-2617 Chandler, AZ  85226  United States Fax: (302) 655-5049f:302 655-5049
This company's Plan of Liquidation went into effect on 2/18/2020
This is a Subsidiary, click here for the Parent Company
Business Summary
Insys Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing and commercializing products to address chemotherapy-induced nausea and vomiting (CINV) pain management and other central nervous system disorders. The Company’s initial product candidate is a dronabinol hard gelatin (Dronabinol HG) capsule. It has filed an abbreviated new drug application (ANDA) for its Dronabinol HG capsule. Its other most advanced product candidates focus on its formulations and delivery methods for dronabinol, the active ingredient in Marinol, and fentanyl, the active ingredient in the pain management drugs Actiq and Fentora. Its internal development pipeline also includes fentanyl and dronabinol line extensions, and other pain management and central nervous system product candidates. In November 2010, Neopharm Inc. completed its merger with the Company.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/201112/31/2010YesYesYes-Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Business Names
Business Name
INRX
Insys Pharma Inc
NeoPharm, Inc.

General Information
Outstanding Shares: 47,908,471 (As of 3/31/2011)
Stock Exchange: NASD
Federal Tax Id: 010749410
Fax Number: (302) 655-5049


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023